Results of Share Purchase Plan
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Syntara Limited announces the successful completion of its Share Purchase Plan, which received strong support from eligible shareholders, totaling significant applications. The funds will be used for clinical trial preparations, licensing discussions, and strengthening the company's patent suite. The company expresses gratitude to shareholders for their support and participation in the Share Purchase Plan.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Syntara
- Share Purchase Plan Offer Booklet
- $8m placement and share purchase plan
- Continuation of trading halt
- Positive FDA feedback for Amsulostat P2b trial
- Half Year Report and Appendix 4D
Later from Syntara
- Encouraging SNT-4728 Phase 2 iRBD results
- Appendix 4E and Annual Report
- Syntara expands SNT-9465 skin scarring study
- Further significant results from SNT-4728 iRBD Phase 2 trial
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara